Co-Authors
This is a "connection" page, showing publications co-authored by JOHN KIRKWOOD and HUSSEIN TAWBI.
Connection Strength
4.240
-
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol. 2013 Apr; 24(4):1112-9.
Score: 0.435
-
Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect. Nat Rev Clin Oncol. 2012 Sep; 9(9):496-7.
Score: 0.427
-
Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treat Rev. 2013 Feb; 39(1):27-43.
Score: 0.418
-
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer. 2011 Sep 06; 105(6):773-7.
Score: 0.398
-
Management of metastatic melanoma. Semin Oncol. 2007 Dec; 34(6):532-45.
Score: 0.308
-
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. Immunotherapy. 2024 Jan; 16(1):29-42.
Score: 0.233
-
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021 11; 9(11).
Score: 0.202
-
Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
Score: 0.170
-
PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy. Sci Rep. 2019 03 01; 9(1):3309.
Score: 0.168
-
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
Score: 0.164
-
Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila). 2018 07; 11(7):429-438.
Score: 0.158
-
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017 09 19; 5(1):74.
Score: 0.152
-
MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin Epigenetics. 2015; 7:58.
Score: 0.130
-
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705.
Score: 0.118
-
Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr Oncol Rep. 2013 Oct; 15(5):483-91.
Score: 0.116
-
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20; 30(3):322-8.
Score: 0.102
-
Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? Nat Clin Pract Oncol. 2009 Feb; 6(2):70-1.
Score: 0.083
-
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clin Cancer Res. 2023 02 01; 29(3):521-531.
Score: 0.055
-
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 2021 03 26; 10(1):1898105.
Score: 0.049
-
The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 05 15; 27(10):2678-2697.
Score: 0.048
-
Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661.
Score: 0.047
-
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.
Score: 0.043
-
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018 Oct 25; JCO1800632.
Score: 0.041
-
Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. Front Oncol. 2018; 8:18.
Score: 0.039
-
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar; 5(3):264-73.
Score: 0.031
-
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology. 2014 Jan 01; 3(1):e27589.
Score: 0.029
-
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8? T cells induced by melanoma vaccines. Cancer Res. 2014 Feb 15; 74(4):1045-55.
Score: 0.029
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov; 13(11):1087-95.
Score: 0.027
-
Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer. 2008 Mar 01; 112(5):1131-8.
Score: 0.020